1695 studies found for:    Open Studies | "Lymphatic Diseases"
Show Display Options
Rank Status Study
21 Not yet recruiting Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology
Conditions: B-Cell Non-Hodgkin Lymphoma;   Chemotherapy-Related Nausea and/or Vomiting;   Childhood Acute Myeloid Leukemia;   Childhood Burkitt Lymphoma;   Childhood Neoplasm;   Febrile Neutropenia;   Hematopoietic Cell Transplantation Recipient;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Other: Informational Intervention;   Other: Interview;   Other: Medical Chart Review
22 Not yet recruiting p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies
Conditions: T-cell Lymphoma;   Aggressive B-cell Lymphoma;   Non-Hodgkin's Lymphomas;   Indolent B-cell Lymphoma
Interventions: Drug: Decitabine;   Drug: Tetrahydrouridine
23 Not yet recruiting Atezolizumab (PD-L1 mAb) in Combination With Obinutuzumab and Ibrutinib in Patients With Relapsed Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL)
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Drug: Obinutuzumab;   Drug: Atezolizumab
24 Recruiting a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies
Conditions: Lymphoma, Large B-Cell, Diffuse;   Leukemia, Lymphocytic, Chronic, B-Cell;   Lymphoma,Malignant
Intervention: Biological: CD19 or CD20 CAR T cells briging HSCT
25 Recruiting LBL-2016 for Children or Adolescents in China
Condition: Lymphoblastic Lymphoma
Interventions: Drug: Prednisone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine;   Drug: 6-mercaptopurine,Methotrexate;   Drug: Dexamethasone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Doxorubicin, 6-mercaptopurine;   Drug: Dexamethasone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Methotrexate;   Drug: Dexamethasone, Vindesine, Methotrexate, Ifosfamide, Daunorubicin, Pegylated-asparaginase;   Drug: Dexamethasone, Cytarabine, Etoposide, Pegylated-asparaginase;   Drug: Methotrexate, 6-mercaptopurine
26 Recruiting Pharmacokinetics & Pharmacodynamics of Diethylcarbamazine (DEC)+ Albendazole (ALB) + Ivermectin (IVE)
Condition: Wuchereria Bancrofti Infection
Intervention: Drug: Ivermectin, Diethylcarbamazine Albendazole (IDA)
27 Not yet recruiting Study of Apatinib and MASCT in Patients With Advanced Solid Tumors
Conditions: Advanced Solid Tumors;   Excluding T Cell Lymphoma
Interventions: Drug: Apatinib;   Biological: MASCT
28 Recruiting Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia
Condition: Waldenström Macroglobulinemia
Interventions: Other: autologous stem cell transplantation;   Other: conventional chemotherapy
29 Recruiting The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia
Condition: Waldenström Macroglobulinemia
Interventions: Drug: Bortezomib;   Drug: Rituximab
30 Recruiting The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM
Condition: Waldenström Macroglobulinemia
Intervention: Drug: Thalidomide
31 Recruiting Combination of Rituximab and NK Immunotherapy for B Lymphoma
Condition: B-cell Lymphoma Recurrent
Interventions: Drug: Rituximab;   Biological: NK immunotherapy
32 Recruiting R-Dose-adjusted (DA) - EPOCH-21 Versus R-modified Non-Hodgkin Lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM)-90 Program (mNHL-BFM-90) and Autologous Stem Cells Transplantation (Auto-SCT) in DLBCL With Poor Prognosis
Condition: Diffuse Large B-Cell Lymphoma
Interventions: Drug: R-DA-EPOCH-21;   Drug: R-DA-EPOCH-21 + auto-SCT;   Drug: R-mNHL-BFM-90;   Drug: R-mNHL-BFM-90 + auto-SCT
33 Not yet recruiting A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (≥ 65 Years) With Haematologic Neoplasms
Conditions: Myelodysplastic Syndromes;   Leukemia Myeloid Acute;   Multiple Myeloma;   Leukemia, Lymphocytic, Chronic, B-Cell
34 Recruiting Autologous CD19 CAR T Cells in Relapsed or Refractory B-cell Lymphoma
Condition: B-cell Lymphoma
Intervention: Biological: autologous anti-CD19 CAR T cells
35 Recruiting Screening of Niemann-Pick Disease, Type C in a Psychiatric Population
Condition: Psychiatric Adults Patients
Interventions: Biological: Blood sampling;   Biological: Biopsy
36 Not yet recruiting Tissue Repository: CTCL Collection Protocol
Conditions: Lymphoma, T-Cell, Cutaneous;   Lymphomatoid Papulosis;   Sézary Syndrome
37 Not yet recruiting Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
Intervention: Drug: Bortezomib, Cytarabine, Dexamethasone, Pegfilgrastim
38 Not yet recruiting Long-Term Follow-Up Study of Clinical Study Subjects Treated With ACTR087
Condition: B Cell Lymphomas
Intervention: Other: ACTR087
39 Recruiting A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
Condition: Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer
Interventions: Drug: Alectinib;   Drug: Crizotinib
40 Recruiting Sofosbuvir+Ledipasvir ±Ribavirin and Sofosbuvir+Ribavirin for Pts With Indolent Bcell Lymphoma Associated With HCV Infection Treatment With Sofosbuvir Plus Ledipasvir ± Ribavirin(G1, 3 and 4) and Sofosbuvir+Ribavirin(G2) for Pts With Hepatitis C Virus Associated Indolent B-cell Lymphomas
Conditions: Indolent B-cell Lymphoma;   Hepatitis C
Interventions: Drug: Sofosbuvir+Ledipasvir;   Drug: Sofosbuvir+Ribavirin;   Drug: Sofosbuvir+Ledipasvir+Ribavirin

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years